



Angiotensin-Converting Enzyme 2 and Anti-Hypertensives (Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors) in Coronavirus Disease 2019 (COVID-19)

Fabian Sanchis-Gomar, MD, PhD; Carl J. Lavie, MD; Carme Perez-Quilis, MD, PhD; Brandon M. Henry, MD; Giuseppe Lippi, MD

PII: S0025-6196(20)30315-3

DOI: <https://doi.org/10.1016/j.mayocp.2020.03.026>

Reference: JMCP 2839

To appear in: JMCP: Mayo Clinic Proceedings

Received Date: 26 March 2020

Revised Date: 27 March 2020

Accepted Date: 30 March 2020

Please cite this article as: Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Angiotensin-converting enzyme 2 and anti-hypertensives (angiotensin receptor blockers and angiotensin converting enzyme inhibitors) in coronavirus disease 2019 (COVID-19) [published online ahead of print March 30, 2020]. *Mayo Clin Proc.* <http://doi.org/10.1016/j.mayocp.2020.03.026>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier on behalf of the Mayo Foundation for Medical Education and Research.

Angiotensin-Converting Enzyme 2 and Anti-Hypertensives (Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors) in Coronavirus Disease 2019 (COVID-19)

Authors:

Fabian Sanchis-Gomar, MD, PhD; Carl J. Lavie, MD; Carme Perez-Quilis, MD, PhD; Brandon M. Henry, MD; Giuseppe Lippi, MD.

Affiliations: From The Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Valencia, Spain (F.S.-G., C.P.-Q.) and Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA (F.S.-G.); John Ochsner Heart and Vascular Institute, Ochsner Clinical School - The University of Queensland School of Medicine, New Orleans, LA, USA (C.J.L.); Cardiac Intensive Care Unit, The Heart Institute, Cincinnati Children's Hospital Medical Center, Ohio, USA (B.M.H.); Section of Clinical Biochemistry, University of Verona, Verona, Italy (G.L.).

[†] *B.M.H. and G.L. share senior authorship in this work*

Correspondence:

Fabian Sanchis-Gomar, MD, PhD

Department of Physiology

Faculty of Medicine

University of Valencia

Av. Blasco Ibañez, 15

46010 Valencia (Spain)

E-mail: fabian.sanchis@uv.es

Abstract

Coronavirus disease 2019 (abbreviated “COVID-19”), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is being defined as the worst pandemic disease of modern times. Several professional health organizations have published position papers stating that there is no evidence to change the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the management of elevated blood pressure (BP) in the context of avoiding or treating COVID-19 infection. In this article, we review the evidence on the relationship between the Renin-Angiotensin-Aldosterone system and COVID-19 infection. In agreement with current guidelines, patients with hypertension should continue taking anti-hypertensive medications as prescribed without interruption. As ACEIs and ARBs are also used to retard the progression of chronic kidney disease (CKD), we suggest that these recommendations also apply to the use of these agents in CKD. No differences generally exist between ARBs and ACEIs in terms of efficacy in decreasing BP and improve other outcomes, such as all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease. ACEIs are associated with cough secondary to accumulation of bradykinin and angioedema, while withdrawal rates due to adverse events are lower with ARBs. Given the equal efficacy but fewer adverse events, ARBs could potentially be a more favorable treatment option in COVID-19 patients at higher risk of developing severe forms of disease.

Keywords: Angiotensin converting enzyme; Hypertension; COVID-19; Coronavirus.

Abbreviations and Acronyms: **ACE** = angiotensin-converting enzyme; **ACEIs** = ACE inhibitors; **ALI** = acute lung injury; **Ang 1-7** = angiotensin 1-7; **Ang I** = Angiotensin I; **Ang II** = angiotensin II; **ARDS** = acute respiratory distress syndrome; **AT₁R** = Ang II type 1 receptor; **AT₂** = type II alveolar cells; **ARBs** = angiotensin receptor blockers; **BP** = blood pressure; **COVID-19** = coronavirus disease 2019; **CV** = cardiovascular; **CVD** = cardiovascular disease; **DM** = diabetes mellitus; **HF** = heart failure; **HTN** = hypertension or hypertensive; **MasR** = Mas receptor; **RAAS** = renin-angiotensin-aldosterone system; **S** = spike; **SARS-CoV-2** = severe acute respiratory syndrome coronavirus 2; **SIRS** = systemic inflammatory response syndrome; **TMPRSS2** = type II transmembrane serine proteases.

INTRODUCTION

The global public-health crisis triggered by coronavirus disease 2019 (abbreviated “COVID-19”), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),¹ is being defined as the worst pandemic disease of modern times.^{2,3} According to the recent statistics from the World Health Organization, this novel coronavirus has already infected nearly 340,000 people worldwide, causing nearly 15,000 deaths.⁴ Alarmingly, between 15-20% (~10-15% severe and ~3-5% critical) of SARS-CoV-2 positive individuals are likely to progress towards a severe form of disease, characterized by interstitial pneumonia, with the potential to evolve into acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), and death.⁵ The high numbers of patients requiring sub-intensive or intensive care can overwhelm many health care infrastructures, even in highly developed countries.⁶

The exponential growth of the contagion around the world has contributed to heightened speculations and concerns over whether two commonly used anti-hypertensive (HTN) drugs, namely, angiotensin-converting enzyme (ACE) inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), also used for cardiovascular (CV) diseases (CVD) and chronic kidney disease (CKD), may exert either deleterious or beneficial effects in COVID-19 patients compared with other drugs used to reduce blood pressure (BP) or to treat heart failure (HF).⁷

Several professional health organizations have published position papers stating that there is no evidence to change the use of ACEIs or ARBs for the management of elevated BP in the context of avoiding or treating COVID-19 infection (Table 1). In this article, we review the evidence on the relationship between the Renin-Angiotensin-Aldosterone system (RAAS) and COVID-19 infection.

COVID-19 AND ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2): ORIGIN OF THE SPECULATION

Healthcare professionals, physicians, researchers, and patients are actively debating the potential influence of ACEIs and ARBs on poor outcomes among COVID-19 patients, based mainly on the evidence that ACE2 is

a functional receptor for coronaviruses, including SARS-CoV-2.⁸ This receptor is located on the surface of type II alveolar cells (AT2) and on lymphocytes, thus explaining the prevalent lung involvement (i.e., interstitial pneumonia and ARDS) and lymphopenia. Moreover, ACE2 is observed on the surface of many other cell types, such as those of the heart, kidney, liver, gastrointestinal tract (especially esophagus, stomach, colon, ileum, rectum) and bladder (Figure 1).⁹⁻¹¹

Kuba et al.¹² first showed that ACE2 is essential for SARS-CoV infection, acting as its effective host receptor *in vivo*. SARS-CoV infection, through binding of viral S protein to ACE2, seems to reduce receptor expression. Injecting SARS-CoV Spike into mice induces acute lung injury (ALI) *in vivo*, which can be mitigated by blocking the RAAS. Wrapp et al.¹³ have recently reported that SARS-CoV-2 binds to ACE2 with 10- to 20-fold higher affinity compared to SARS-CoV. Specifically, the S protein of SARS-CoV-2 virus binds to the catalytic domain of ACE2 inducing internalization of the virus by the cell.

In brief, the RAAS is the central regulatory system for BP control.¹⁴ Additionally, RAAS activation plays a crucial pathogenic role in HTN, through hemodynamic actions and cytokines and intracellular signaling pathways, which ultimately promote many adverse cellular processes implicated in systemic damage.¹⁴ In the RAAS, Angiotensin I (Ang I) is converted to angiotensin II (Ang II) by ACE. Ang II mediates vasoconstrictive, pro-inflammatory and pro-oxidative effects through agonism at Ang II type 1 receptor (AT₁R).¹⁵ ACE2 converts Ang II to angiotensin 1-7 (Ang1-7), which finally binds to Mas receptor (MasR) and mediates many beneficial actions, including vasodilation and anti-inflammatory, anti-oxidant and anti-apoptotic effects.¹⁵ Thus, ACE2/Ang1-7/MasR axis has opposite actions to ACE/AngII/AT₁R axis (Figure 2).

ACE2, a homologue of ACE, is an integral cell membrane protein with a catalytic domain on the extracellular surface exposed to vasoactive peptides.¹⁶ ACE2 is a monocarboxypeptidase whose major role is converting Ang II to Ang 1-7,¹⁶ with vasodilatory and antifibrotic actions¹⁷ when it activates MasR.¹⁸ Moreover, ACE2 also converts Ang I to Ang 1-9 which can be further converted by ACE into Ang 1-7. Thus, ACE2 limits the adverse vasoconstrictor and profibrotic effects of Ang II through its degradation and by counteracting its actions through the formation of Ang 1-7. The high expression of ACE2 in heart, type II

alveolar cells (AT2), capillary endothelium¹⁹ and enterocytes,²⁰ demonstrates its essential role in CV and immune systems,²⁰ being principally involved in heart function and the development of HTN and complications of diabetes mellitus (DM).

As previously discussed, SARS-CoV-2 penetrates the cell through ACE2, but also necessitates type II transmembrane serine proteases (TMPRSS2) for effective priming of viral Spike (S) protein. The binding of coronavirus S protein to ACE2 triggers a conformational change in the S protein, allowing for proteolytic digestion by TMPRSS2, which enables viral and cell membrane fusion.²¹ This was recently confirmed by the evidence that camostat mesylate, a protease TMPRSS2 inhibitor, blocks viral entry and may be a promising drug for SARS-CoV-2 infection.^{21, 22} As ACE2 is a functional receptor for SARS- CoV-2, many healthcare professionals have begun to reconsider the safety and effects of anti-HTN therapy with ACEIs or ARBs in patients during the COVID-19 outbreak-; and, despite statements by medical organizations, they began to question whether patients with COVID-19 and HTN maintained on ACEIs or ARBs to decrease BP values (or for other conditions such as CVD and CKD) should change to another anti-HTN pharmacological agent.²³ Such considerations contributed to the current controversy.

THE USE OF ARBs OR ACEIs IN PATIENTS AT HIGH RISK OF SEVERE COVID-19: DELETERIOUS OR BENEFICIAL?

It has been hypothesized that increased levels of ACE2 may facilitate COVID-19 infection, such that administering ARBs or ACEIs might increase the risk of developing severe and fatal COVID-19.²⁴⁻²⁶ As discussed later in this section, this premise is based in part on the findings in some, but not all, studies that ARBs and ACEIs may increase ACE2 levels. According to the most recent studies on COVID-19, it appears that HTN is one of the most important factors associated with poor prognosis at an early stage of COVID-19 infection.²⁷⁻³² HTN, however, has also been found to be associated with decreased baseline levels of ACE2 expression. Unfortunately, most of these early COVID-19 studies have not been adjusted for age or other comorbidities. The last report on the characteristics of deceased COVID-19 positive patients in Italy officially released on March 20, 2020 by the Italian Ministry of Health through the National Institute of Health

(Istituto Superiore di Sanità; ISS) showed that the most common concurrent medical co-morbidities observed were arterial HTN (73.8%; 355 of 481), DM (33.9%; 163 of 481), ischemic cardiopathy (30.1%; 145 of 481), and atrial fibrillation (22%; 106 of 481).³³ Prior to hospitalization, 36% (173 of 481) of fatal COVID-19 patients were on treatment with ACEIs, while 16% (77 of 481) were on treatment with ARBs (odds ratio, 2.26; 95% confidence interval, 95% CI, 1.66-3.09; $p < 0.001$). Nevertheless, these numbers are preliminary and may not precisely reflect adjusted differences in risk. It is virtually impossible to precisely identify all medical therapies before admission from medical records³³. Moreover, patients with elevated BP on admission may be noted to have a history of chronic HTN in their medical record, and such coding may reflect provider biases from the current infectious illness. The median age of SARS-CoV-2 positive patients who died was 78.5 years (median: 80 years; range: 31-103 years; interquartile range, 73-85 years). Since HTN prevalence increases in parallel with aging, this pattern may represent the expected prevalence for the given age group. Therefore, although the number of fatal COVID-19 positive patients treated with ACEIs was more than twice the number of those treated with ARBs, one cannot definitely conclude risks or benefits of these therapies due to confounding variables of age, HTN, as well as the impact of yet unidentified comorbidities on outcome with the COVID-19 pandemic.

In a recent study, in which potential drugs targeting SARS-CoV-2 were evaluated, the authors reported that ARBs (e.g., irbesartan) may associate with some human coronaviruses-associated host proteins in the human interactome.³⁴ Irbesartan targets the *SLC10A1* gene (solute carrier family 10 member 1), which interacts with *C11orf74* gene, a potential transcriptional repressor that interacts with the non-structural protein 10 (NSP10) of SARS-CoV and participates in CoV replication fidelity.³⁵

Crackower and co-workers³⁶ reported that disruption of ACE2 results in increased Ang II levels and impaired cardiac function, whereas other authors showed that ACE2 overexpression reduced left ventricular hypertrophy and myocardial fibrosis in HTN rats.³⁷ Lower cardiac ACE2 concentrations are observed in HTN,^{37, 38} CVD associated with DM,³⁹ and Ang II-induced cardiac dysfunction,⁴⁰ suggesting that augmenting ACE2 could have beneficial therapeutic effects on the CV system. In numerous studies carried out in animal models, both ACEIs and ARBs may increase ACE2 expression or levels,⁴¹⁻⁴⁵ though other authors failed to observe such increases.^{46, 47} Importantly, no studies have reported an increase in circulating ACE2 levels

and/or expression thus far^{48, 49} and increased expression would not necessarily imply increased risk of infection or disease severity.

Deshotels et al.⁵⁰ investigated the compensatory reduction of ACE2 expression and activity in response to Ang II-mediated HTN. Elevated levels of Ang II decreased ACE2 activity on the cell surface via an AT₁R-dependent internalization mechanism.⁵⁰ Moreover, *in vitro* treatment of HEK293T cells with Ang II enhanced ACE2 ubiquitination also mediated by AT₁R, which ultimately stimulates ACE2 lysosomal degradation (which might prevent interaction of the SARS-Co-V2 with ACE2 catalytic site).⁵⁰ This is reported to be prevented by AT₁R antagonist losartan which may block internalization, proteolytic degradation and ubiquitination of ACE2.⁵⁰ As such, this latter pathway represents another mechanism by which ACEIs or ARBs could prevent COVID-19 viral entry. If the viral protein interaction with ACE2 is reduced in the presence of stabilized ACE2-AT₁R complexes, then ARBs could prove beneficial by stabilizing ACE2-AT₁R interaction and preventing viral protein-ACE2 interaction and internalization. Based on this mechanism of action, Gurwitz recently suggests ARBs (losartan and telmisartan) as a tentative therapy for COVID-19 patients prior to the development of ALI/acute respiratory failure.⁵¹ However, it remains unknown whether preventing ACE2 internalization would be effective at attenuating infections by SARS coronaviruses, and further studies are urgently needed to clarify this mechanism.

Interestingly, Liu et al.⁵² reported serum Ang II levels were significantly higher in COVID-19 infected than non-infected individuals and linearly associated with viral load and lung damage. It is suspected that Ang II, via pulmonary vasoconstriction leading to decrease flow and ventilation/perfusion mismatch and via increased vascular permeability and its proinflammatory and pro-oxidative properties, may induce or perpetuate ARDS in a variety of pathologies.⁵³ The findings by Liu et al.⁵² would support the hypothesis that elevated levels of Ang II may foster ARDS in COVID-19 patients. Nevertheless, this study has important limitations as it was performed in a limited sample and, as such, require confirmation.⁵²

The role of RAAS peptides in acute lung injury has been also investigated in other ARDS patients (diagnosed within 24 hours) by using a targeted metabolomics approach.⁵⁴ Ang I concentrations were significantly higher in non-survivors at study entry and at 72 hours, while ARDS survival was associated with lower Ang I levels but higher Ang 1-9 concentration (a precursor to Ang 1-7). Survivors showed a

significantly higher average Ang 1–9/Ang I and Ang 1–7/Ang I ratios, which suggests that ACE2 activity is higher in survivors than non-survivors.⁵⁴ Therefore, ACE2 activities seems to be reduced in patients who succumb from ARDS.

Further downstream, high levels of Ang II, which may be due to attenuated ACE2, such as that potentially caused by the SARS-CoV-2 interaction with ACE2, stimulates increased production of aldosterone. Aldosterone in turn increases ACE activity inducing further production of Ang II, leading to a potentially vicious cycle which perpetuates ARDS.⁵⁵ Moreover, aldosterone decreases expression of the MasR, minimizing the antagonizing benefits of any Ang 1-7 produced by ACE2. As such, aldosterone receptor blockers or aldosterone synthase inhibitors may have a potential role in COVID-19 therapy; however, careful evaluation of any influence on corticosteroids synthesis and signaling is required.⁵⁵

Since SARS-CoV-2 invades alveolar epithelial cells, respiratory symptoms are often the most common reported, and is reported to be more severe in patients with CVD.²³ This might be associated with higher ACE2 levels, which has been suggested to be increased in patients maintained on RAAS inhibitors.²³ However, in a study conducted in rats by Xudong et al.,⁵⁶ ACE2 expression dramatically decreased with age in both genders, while older male rats also had lower ACE2 concentrations than did older female rats. Whether such altered profiles of ACE2 are similarly observed in humans, or if ACE2 expression is altered in disease, requires further investigation.

It has also been recently demonstrated that recombinant ACE2 administration in mice with ARDS protects from development of ALI and severe lung disease, thus strongly suggesting that ACE2 mediates a cytoprotective role in ALI,⁵⁷ whether such effects are also observed in ARDS caused by COVID-19 is unknown at this time. Thus extrapolating from these and previously discussed findings, one may speculate that the administration of recombinant ACE2 or its product Ang 1-7, which directly opposes Ang II, may offer potentially beneficial effects in SARS-CoV-2-associated ARDS.⁵⁷ Moreover, specifically with SARS-CoV-2, recombinant ACE2 may serve the role as a competitive inhibitor, binding up viral particles that would otherwise bind to membrane bound ACE2, thus decreasing viral load and protecting/increasing residual endogenous membrane bound ACE2. Studies that directly administer recombinant ACE2 to mice in conjunction with those that utilize ACE2 knockout mice demonstrated that ACE2 protects murine lungs from

ARDS. Such an approach in preclinical studies of ARDS specifically due to COVID-19 is especially important and timely.

CONCLUSIONS AND POTENTIAL RECOMMENDATIONS

SARS-CoV-2 binding to ACE2 may attenuate residual ACE2 activity, further tipping the ACE/ACE2 balance to a predominant ACE/AngII/AT1 axis signaling, in which AngII may then foster pulmonary vasoconstriction, and inflammatory and oxidative organ damage, ultimately progressing towards ALI/ARDS.⁵³ We speculate that RAAS dysregulation may play a central role in the pathophysiology of COVID-19 associated ALI/ARDS, but definitive studies that address this issue are needed. Whether RAAS modulation may have a beneficial effect in selected patients with severe COVID-19 at risk for ALI/ARDS is entirely unknown at the present time. Moreover, the effects of other agents that may interrupt the RAAS by inhibiting renin, such as renin inhibitors and beta-blockers, would also be of interest regarding their effects on COVID-19 and attendant ALI.

In agreement with current guidelines, patients with HTN should continue taking anti-HTN medications as prescribed without interruption. Current evidence shows that RAAS inhibitors, i.e., ACEIs and ARBs, significantly reduce mortality in CVD, reduce the progression of CKD, and are the cornerstone of HF and HTN treatment. ACEIs or ARBs therapy should be maintained or initiated, as indicated, in patients with HF, HTN, or myocardial infarction, regardless of SARS-CoV-2. No differences exist between ARBs and ACEIs in terms of efficacy to decrease BP and improve other outcomes, such as all-cause mortality, CVD mortality, myocardial infarction, HF, stroke, and end-stage renal disease.⁵⁸ ACEIs are associated with cough secondary to accumulation of bradykinin and angioedema, while withdrawal rates due to adverse events are lower with ARBs.⁵⁸ Given the equal efficacy but fewer adverse events, ARBs could potentially be a more favorable treatment option in COVID-19 patients at higher risk of developing severe forms of disease (Table 2). To further evaluate the role of RAAS modulation in COVID-19, datasets should be analyzed to investigate if use of ACEIs and ARBs on admission could be associated with ALI/ARDS and/or survival/mortality in patients with DM, HTN and CVD.

Finally, the potential utility of alternative therapies, such as recombinant ACE2, Ang 1-7 peptides, angiotensin II receptor inhibitors, and potentially aldosterone synthase inhibitors, for preventing or mitigating ALI caused by viruses, is entirely unknown at the present time and requires consideration and investigation for a disease for which current care is entirely supportive.

ACKNOWLEDGEMENTS

Fabian Sanchis-Gomar is supported by a postdoctoral contract granted by “*Subprograma Atracció de Talent - Contractes Postdoctorals de la Universitat de València.*”

Potential Competing Interests: The authors have no association with commercial entities that could be viewed as having an interest in the general area of the submitted manuscript.

REFERENCES

1. Shah A, Kashyap R, Tosh P, Sampathkumar P, O’Horo JC. Guide to Understanding the 2019 Novel Coronavirus. *Mayo Clin Proc.* 2020; doi: <https://doi.org/10.1016/j.mayocp.2020.02.003>.
2. Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. *BMJ.* 2020;368:m1036.
3. Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. *Ann Transl Med* 2020; doi: 10.21037/atm.2020.03.157.
4. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 62. Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>. Last accessed: March 25, 2020.
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA.* 2020;doi: 10.1001/jama.2020.2648.
6. Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. *New England Journal of Medicine.* 2020.
7. Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? *Eur Heart J.* 2020.

8. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J Virol.* 2020;94.
9. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front Med.* 2020.
10. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci.* 2020;12:8.
11. Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. *Biochem Biophys Res Commun.* 2020.
12. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med.* 2005;11:875-879.
13. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science.* 2020;367:1260-1263.
14. Velkoska E, Patel SK, Burrell LM. Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation. *Curr Opin Nephrol Hypertens.* 2016;25:384-395.
15. Tikellis C, Thomas MC. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. *Int J Pept.* 2012;2012:256294.
16. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circ Res.* 2000;87:E1-9.
17. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). *Hypertension.* 2003;42:574-579.
18. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. *Proc Natl Acad Sci U S A.* 2003;100:8258-8263.
19. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol.* 2004;203:631-637.
20. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. *Trends Pharmacol Sci.* 2004;25:291-294.
21. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell.* 2020.
22. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A.* 2020.
23. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol.* 2020.
24. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *The Lancet Respiratory Medicine.* 2020.
25. Watkins J. Preventing a covid-19 pandemic. *BMJ.* 2020;368:m810.

26. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? *J Hypertens*. 2020.
27. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020.
28. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020.
29. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.
30. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020.
31. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020.
32. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020.
33. Report sulle caratteristiche dei pazienti deceduti positivi a COVID-19 in Italia, 20 Marzo 2020. Available at: https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo.pdf. Last accessed: March 23, 2020.
34. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discovery*. 2020;6:14.
35. Hong M, Li W, Wang L, et al. Identification of a novel transcriptional repressor (HEPIS) that interacts with nsp-10 of SARS coronavirus. *Viral Immunol*. 2008;21:153-162.
36. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature*. 2002;417:822-828.
37. Diez-Freire C, Vazquez J, Correa de Adjoulian MF, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. *Physiol Genomics*. 2006;27:12-19.
38. Ferreira AJ, Shenoy V, Qi Y, et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. *Exp Physiol*. 2011;96:287-294.
39. Tikellis C, Pickering R, Tsorotes D, et al. Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. *Clin Sci (Lond)*. 2012;123:519-529.
40. Patel VB, Clarke N, Wang Z, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. *J Mol Cell Cardiol*. 2014;66:167-176.
41. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation*. 2005;111:2605-2610.
42. Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. *Hypertension*.

2006;48:572-578.

- 43.** Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. *Hypertension*. 2004;43:970-976.
- 44.** Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. *Am J Physiol Renal Physiol*. 2009;296:F398-405.
- 45.** Klimas J, Olvedy M, Ochodnicka-Mackovicova K, et al. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. *J Cell Mol Med*. 2015;19:1965-1974.
- 46.** Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. *Clin Sci (Lond)*. 2012;123:649-658.
- 47.** Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. *Eur Heart J*. 2005;26:369-375; discussion 322-364.
- 48.** Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. *Europace*. 2017;19:1280-1287.
- 49.** Ramchand J, Patel SK, Srivastava PM, Farouque O, Burrell LM. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. *PLoS One*. 2018;13:e0198144.
- 50.** Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. *Hypertension*. 2014;64:1368-1375.
- 51.** Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. *Drug Dev Res*. 2020.
- 52.** Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci*. 2020;63:364-374.
- 53.** Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. *Crit Care*. 2017;21:305.
- 54.** Reddy R, Asante I, Liu S, et al. Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study. *PLoS One*. 2019;14:e0213096.
- 55.** Stoll D, Yokota R, Sanches Aragao D, Casarini DE. Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG (1-7)/MAS receptor axes in human mesangial cells. *Physiol Rep*. 2019;7:e14105.
- 56.** Xie X, Chen J, Wang X, Zhang F, Liu Y. Age- and gender-related difference of ACE2 expression in rat lung. *Life Sci*. 2006;78:2166-2171.

57. Gu H, Xie Z, Li T, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. *Sci Rep*. 2016;6:19840.



58. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? *J Am Coll Cardiol*. 2018;71:1474-1482.

59. Sparks MA, Hiremath S et al. The coronavirus conundrum: ACE2 and hypertension edition. *NephJC*. <http://www.nephjc.com/news/covidace2> . Accessed March 27, 2020.

Figure legends

Figure 1. Localization of ACE2 protein in human organs and tissues.

Figure 2. Scheme of Renin-Angiotensin-Aldosterone system and SARS-CoV-2 infection mechanism.

Table 1. Professional societies recommendations following the statements on the issue.  Recommended continuing ARBs and ACEIs.  Recommended continuing angiotensin receptor neprilysin inhibitors.

Adapted from *NephJC*.⁵⁹. Used with permission.















	Date of publication	Recommendation
European Society of Hypertension	March 12, 2020	
European Society of Cardiology Council on Hypertension	March 13, 2020	
Hypertension Canada	March 13, 2020	
Canadian Cardiovascular Society	March 15, 2020	 
The Renal Association, United Kingdom	March 15, 2020	
International Society of Hypertension	March 16, 2020	
American College of Physicians	March 16, 2020	
Spanish Society of Hypertension	March 16, 2020	
American Heart Association	March 17, 2020	
Heart Failure Society of America	March 17, 2020	
American College of Cardiology	March 17, 2020	
European Renal Association, European Dialysis and Transplant Association	March 17, 2020	
High Blood Pressure Research Council of Australia	March 18, 2020	

Table 2. Risk factors related with worse prognosis in COVID-19 patients.

Age (>65 years)
Current smoker
Hypertension
Diabetes
Coronary heart disease
Atrial fibrillation
Chronic obstructive lung disease
Chronic kidney disease
Cancer
Obesity (BMI >30)

Angiotensin-Converting Enzyme 2 and Anti-Hypertensives (Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors) in Coronavirus Disease 2019 (COVID-19)

Authors:

Fabian Sanchis-Gomar, MD, PhD; Carl J. Lavie, MD; Carme Perez-Quilis, MD, PhD; Brandon M. Henry, MD; Giuseppe Lippi, MD.

Affiliations: From The Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Valencia, Spain (F.S.-G., C.P.-Q.) and Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA (F.S.-G.); John Ochsner Heart and Vascular Institute, Ochsner Clinical School - The University of Queensland School of Medicine, New Orleans, LA, USA (C.J.L.); Cardiac Intensive Care Unit, The Heart Institute, Cincinnati Children's Hospital Medical Center, Ohio, USA (B.M.H.); Section of Clinical Biochemistry, University of Verona, Verona, Italy (G.L.).

[†]*B.M.H. and G.L. share senior authorship in this work*

Correspondence:

Fabian Sanchis-Gomar, MD, PhD

Department of Physiology

Faculty of Medicine

University of Valencia

Av. Blasco Ibañez, 15

46010 Valencia (Spain)

E-mail: fabian.sanchis@uv.es

Abstract

Coronavirus disease 2019 (abbreviated “COVID-19”), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is being defined as the worst pandemic disease of modern times. Several professional health organizations have published position papers stating that there is no evidence to change the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the management of elevated blood pressure (BP) in the context of avoiding or treating COVID-19 infection. In this article, we review the evidence on the relationship between the Renin-Angiotensin-Aldosterone system and COVID-19 infection. In agreement with current guidelines, patients with hypertension should continue taking anti-hypertensive medications as prescribed without interruption. As ACEIs and ARBs are also used to retard the progression of chronic kidney disease (CKD), we suggest that these recommendations also apply to the use of these agents in CKD. No differences generally exist between ARBs and ACEIs in terms of efficacy in decreasing BP and improve other outcomes, such as all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease. ACEIs are associated with cough secondary to accumulation of bradykinin and angioedema, while withdrawal rates due to adverse events are lower with ARBs. Given the equal efficacy but fewer adverse events, ARBs could potentially be a more favorable treatment option in COVID-19 patients at higher risk of developing severe forms of disease.

Keywords: Angiotensin converting enzyme; Hypertension; COVID-19; Coronavirus.

Abbreviations and Acronyms: ACE = angiotensin-converting enzyme; ACEIs = ACE inhibitors; ALI = acute lung injury; Ang 1-7 = angiotensin 1-7; Ang I = Angiotensin I; Ang II = angiotensin II; ARDS = acute respiratory distress syndrome; AT₁R = Ang II type 1 receptor; AT₂ = type II alveolar cells; ARBs = angiotensin receptor blockers; BP = blood pressure; COVID-19 = coronavirus disease 2019; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; HF = heart failure; HTN = hypertension or hypertensive; MasR = Mas receptor; RAAS = renin-angiotensin-aldosterone system; S = spike; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SIRS = systemic inflammatory response syndrome; TMPRSS2 = type II transmembrane serine proteases.

INTRODUCTION

The global public-health crisis triggered by coronavirus disease 2019 (abbreviated “COVID-19”), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),¹ is being defined as the worst pandemic disease of modern times.^{2,3} According to the recent statistics from the World Health Organization, this novel coronavirus has already infected nearly 340,000 people worldwide, causing nearly 15,000 deaths.⁴ Alarmingly, between 15-20% (~10-15% severe and ~3-5% critical) of SARS-CoV-2 positive individuals are likely to progress towards a severe form of disease, characterized by interstitial pneumonia, with the potential to evolve into acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), and death.⁵ The high numbers of patients requiring sub-intensive or intensive care can overwhelm many health care infrastructures, even in highly developed countries.⁶

The exponential growth of the contagion around the world has contributed to heightened speculations and concerns over whether two commonly used anti-hypertensive (HTN) drugs, namely, angiotensin-converting enzyme (ACE) inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), also used for cardiovascular (CV) diseases (CVD) and chronic kidney disease (CKD), may exert either deleterious or beneficial effects in COVID-19 patients compared with other drugs used to reduce blood pressure (BP) or to treat heart failure (HF).⁷

Several professional health organizations have published position papers stating that there is no evidence to change the use of ACEIs or ARBs for the management of elevated BP in the context of avoiding or treating COVID-19 infection (Table 1). In this article, we review the evidence on the relationship between the Renin-Angiotensin-Aldosterone system (RAAS) and COVID-19 infection.

COVID-19 AND ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2): ORIGIN OF THE SPECULATION

Healthcare professionals, physicians, researchers, and patients are actively debating the potential influence of ACEIs and ARBs on poor outcomes among COVID-19 patients, based mainly on the evidence that ACE2 is

a functional receptor for coronaviruses, including SARS-CoV-2.⁸ This receptor is located on the surface of type II alveolar cells (AT2) and on lymphocytes, thus explaining the prevalent lung involvement (i.e., interstitial pneumonia and ARDS) and lymphopenia. Moreover, ACE2 is observed on the surface of many other cell types, such as those of the heart, kidney, liver, gastrointestinal tract (especially esophagus, stomach, colon, ileum, rectum) and bladder (Figure 1).⁹⁻¹¹

Kuba et al.¹² first showed that ACE2 is essential for SARS-CoV infection, acting as its effective host receptor *in vivo*. SARS-CoV infection, through binding of viral S protein to ACE2, seems to reduce receptor expression. Injecting SARS-CoV Spike into mice induces acute lung injury (ALI) *in vivo*, which can be mitigated by blocking the RAAS. Wrapp et al.¹³ have recently reported that SARS-CoV-2 binds to ACE2 with 10- to 20-fold higher affinity compared to SARS-CoV. Specifically, the S protein of SARS-CoV-2 virus binds to the catalytic domain of ACE2 inducing internalization of the virus by the cell.

In brief, the RAAS is the central regulatory system for BP control.¹⁴ Additionally, RAAS activation plays a crucial pathogenic role in HTN, through hemodynamic actions and cytokines and intracellular signaling pathways, which ultimately promote many adverse cellular processes implicated in systemic damage.¹⁴ In the RAAS, Angiotensin I (Ang I) is converted to angiotensin II (Ang II) by ACE. Ang II mediates vasoconstrictive, pro-inflammatory and pro-oxidative effects through agonism at Ang II type 1 receptor (AT₁R).¹⁵ ACE2 converts Ang II to angiotensin 1-7 (Ang1-7), which finally binds to Mas receptor (MasR) and mediates many beneficial actions, including vasodilation and anti-inflammatory, anti-oxidant and anti-apoptotic effects.¹⁵ Thus, ACE2/Ang1-7/MasR axis has opposite actions to ACE/AngII/AT₁R axis (Figure 2).

ACE2, a homologue of ACE, is an integral cell membrane protein with a catalytic domain on the extracellular surface exposed to vasoactive peptides.¹⁶ ACE2 is a monocarboxypeptidase whose major role is converting Ang II to Ang 1-7,¹⁶ with vasodilatory and antifibrotic actions¹⁷ when it activates MasR.¹⁸ Moreover, ACE2 also converts Ang I to Ang 1-9 which can be further converted by ACE into Ang 1-7. Thus, ACE2 limits the adverse vasoconstrictor and profibrotic effects of Ang II through its degradation and by counteracting its actions through the formation of Ang 1-7. The high expression of ACE2 in heart, type II

alveolar cells (AT2), capillary endothelium¹⁹ and enterocytes,²⁰ demonstrates its essential role in CV and immune systems,²⁰ being principally involved in heart function and the development of HTN and complications of diabetes mellitus (DM).

As previously discussed, SARS-CoV-2 penetrates the cell through ACE2, but also necessitates type II transmembrane serine proteases (TMPRSS2) for effective priming of viral Spike (S) protein. The binding of coronavirus S protein to ACE2 triggers a conformational change in the S protein, allowing for proteolytic digestion by TMPRSS2, which enables viral and cell membrane fusion.²¹ This was recently confirmed by the evidence that camostat mesylate, a protease TMPRSS2 inhibitor, blocks viral entry and may be a promising drug for SARS-CoV-2 infection.^{21, 22} As ACE2 is a functional receptor for SARS- CoV-2, many healthcare professionals have begun to reconsider the safety and effects of anti-HTN therapy with ACEIs or ARBs in patients during the COVID-19 outbreak-; and, despite statements by medical organizations, they began to question whether patients with COVID-19 and HTN maintained on ACEIs or ARBs to decrease BP values (or for other conditions such as CVD and CKD) should change to another anti-HTN pharmacological agent.²³ Such considerations contributed to the current controversy.

THE USE OF ARBs OR ACEIs IN PATIENTS AT HIGH RISK OF SEVERE COVID-19: DELETERIOUS OR BENEFICIAL?

It has been hypothesized that increased levels of ACE2 may facilitate COVID-19 infection, such that administering ARBs or ACEIs might increase the risk of developing severe and fatal COVID-19.²⁴⁻²⁶ As discussed later in this section, this premise is based in part on the findings in some, but not all, studies that ARBs and ACEIs may increase ACE2 levels. According to the most recent studies on COVID-19, it appears that HTN is one of the most important factors associated with poor prognosis at an early stage of COVID-19 infection.²⁷⁻³² HTN, however, has also been found to be associated with decreased baseline levels of ACE2 expression. Unfortunately, most of these early COVID-19 studies have not been adjusted for age or other comorbidities. The last report on the characteristics of deceased COVID-19 positive patients in Italy officially released on March 20, 2020 by the Italian Ministry of Health through the National Institute of Health

(Istituto Superiore di Sanità; ISS) showed that the most common concurrent medical co-morbidities observed were arterial HTN (73.8%; 355 of 481), DM (33.9%; 163 of 481), ischemic cardiopathy (30.1%; 145 of 481), and atrial fibrillation (22%; 106 of 481).³³ Prior to hospitalization, 36% (173 of 481) of fatal COVID-19 patients were on treatment with ACEIs, while 16% (77 of 481) were on treatment with ARBs (odds ratio, 2.26; 95% confidence interval, 95% CI, 1.66-3.09; $p < 0.001$). Nevertheless, these numbers are preliminary and may not precisely reflect adjusted differences in risk. It is virtually impossible to precisely identify all medical therapies before admission from medical records³³. Moreover, patients with elevated BP on admission may be noted to have a history of chronic HTN in their medical record, and such coding may reflect provider biases from the current infectious illness. The median age of SARS-CoV-2 positive patients who died was 78.5 years (median: 80 years; range: 31-103 years; interquartile range, 73-85 years). Since HTN prevalence increases in parallel with aging, this pattern may represent the expected prevalence for the given age group. Therefore, although the number of fatal COVID-19 positive patients treated with ACEIs was more than twice the number of those treated with ARBs, one cannot definitely conclude risks or benefits of these therapies due to confounding variables of age, HTN, as well as the impact of yet unidentified comorbidities on outcome with the COVID-19 pandemic.

In a recent study, in which potential drugs targeting SARS-CoV-2 were evaluated, the authors reported that ARBs (e.g., irbesartan) may associate with some human coronaviruses-associated host proteins in the human interactome.³⁴ Irbesartan targets the *SLC10A1* gene (solute carrier family 10 member 1), which interacts with *C11orf74* gene, a potential transcriptional repressor that interacts with the non-structural protein 10 (NSP10) of SARS-CoV and participates in CoV replication fidelity.³⁵

Crackower and co-workers³⁶ reported that disruption of ACE2 results in increased Ang II levels and impaired cardiac function, whereas other authors showed that ACE2 overexpression reduced left ventricular hypertrophy and myocardial fibrosis in HTN rats.³⁷ Lower cardiac ACE2 concentrations are observed in HTN,^{37,38} CVD associated with DM,³⁹ and Ang II-induced cardiac dysfunction,⁴⁰ suggesting that augmenting ACE2 could have beneficial therapeutic effects on the CV system. In numerous studies carried out in animal models, both ACEIs and ARBs may increase ACE2 expression or levels,⁴¹⁻⁴⁵ though other authors failed to observe such increases.^{46, 47} Importantly, no studies have reported an increase in circulating ACE2 levels

and/or expression thus far^{48, 49} and increased expression would not necessarily imply increased risk of infection or disease severity.

Deshotels et al.⁵⁰ investigated the compensatory reduction of ACE2 expression and activity in response to Ang II-mediated HTN. Elevated levels of Ang II decreased ACE2 activity on the cell surface via an AT₁R-dependent internalization mechanism.⁵⁰ Moreover, *in vitro* treatment of HEK293T cells with Ang II enhanced ACE2 ubiquitination also mediated by AT₁R, which ultimately stimulates ACE2 lysosomal degradation (which might prevent interaction of the SARS-Co-V2 with ACE2 catalytic site).⁵⁰ This is reported to be prevented by AT₁R antagonist losartan which may block internalization, proteolytic degradation and ubiquitination of ACE2.⁵⁰ As such, this latter pathway represents another mechanism by which ACEIs or ARBs could prevent COVID-19 viral entry. If the viral protein interaction with ACE2 is reduced in the presence of stabilized ACE2-AT₁R complexes, then ARBs could prove beneficial by stabilizing ACE2-AT₁R interaction and preventing viral protein-ACE2 interaction and internalization. Based on this mechanism of action, Gurwitz recently suggests ARBs (losartan and telmisartan) as a tentative therapy for COVID-19 patients prior to the development of ALI/acute respiratory failure.⁵¹ However, it remains unknown whether preventing ACE2 internalization would be effective at attenuating infections by SARS coronaviruses, and further studies are urgently needed to clarify this mechanism.

Interestingly, Liu et al.⁵² reported serum Ang II levels were significantly higher in COVID-19 infected than non-infected individuals and linearly associated with viral load and lung damage. It is suspected that Ang II, via pulmonary vasoconstriction leading to decrease flow and ventilation/perfusion mismatch and via increased vascular permeability and its proinflammatory and pro-oxidative properties, may induce or perpetuate ARDS in a variety of pathologies.⁵³ The findings by Liu et al.⁵² would support the hypothesis that elevated levels of Ang II may foster ARDS in COVID-19 patients. Nevertheless, this study has important limitations as it was performed in a limited sample and, as such, require confirmation.⁵²

The role of RAAS peptides in acute lung injury has been also investigated in other ARDS patients (diagnosed within 24 hours) by using a targeted metabolomics approach.⁵⁴ Ang I concentrations were significantly higher in non-survivors at study entry and at 72 hours, while ARDS survival was associated with lower Ang I levels but higher Ang 1-9 concentration (a precursor to Ang 1-7). Survivors showed a

significantly higher average Ang 1–9/Ang I and Ang 1–7/Ang I ratios, which suggests that ACE2 activity is higher in survivors than non-survivors.⁵⁴ Therefore, ACE2 activities seems to be reduced in patients who succumb from ARDS.

Further downstream, high levels of Ang II, which may be due to attenuated ACE2, such as that potentially caused by the SARS-CoV-2 interaction with ACE2, stimulates increased production of aldosterone. Aldosterone in turn increases ACE activity inducing further production of Ang II, leading to a potentially vicious cycle which perpetuates ARDS.⁵⁵ Moreover, aldosterone decreases expression of the MasR, minimizing the antagonizing benefits of any Ang 1-7 produced by ACE2. As such, aldosterone receptor blockers or aldosterone synthase inhibitors may have a potential role in COVID-19 therapy; however, careful evaluation of any influence on corticosteroids synthesis and signaling is required.⁵⁵

Since SARS-CoV-2 invades alveolar epithelial cells, respiratory symptoms are often the most common reported, and is reported to be more severe in patients with CVD.²³ This might be associated with higher ACE2 levels, which has been suggested to be increased in patients maintained on RAAS inhibitors.²³ However, in a study conducted in rats by Xudong et al.,⁵⁶ ACE2 expression dramatically decreased with age in both genders, while older male rats also had lower ACE2 concentrations than did older female rats. Whether such altered profiles of ACE2 are similarly observed in humans, or if ACE2 expression is altered in disease, requires further investigation.

It has also been recently demonstrated that recombinant ACE2 administration in mice with ARDS protects from development of ALI and severe lung disease, thus strongly suggesting that ACE2 mediates a cytoprotective role in ALI,⁵⁷ whether such effects are also observed in ARDS caused by COVID-19 is unknown at this time. Thus extrapolating from these and previously discussed findings, one may speculate that the administration of recombinant ACE2 or its product Ang 1-7, which directly opposes Ang II, may offer potentially beneficial effects in SARS-CoV-2-associated ARDS.⁵⁷ Moreover, specifically with SARS-CoV-2, recombinant ACE2 may serve the role as a competitive inhibitor, binding up viral particles that would otherwise bind to membrane bound ACE2, thus decreasing viral load and protecting/increasing residual endogenous membrane bound ACE2. Studies that directly administer recombinant ACE2 to mice in conjunction with those that utilize ACE2 knockout mice demonstrated that ACE2 protects murine lungs from

ARDS. Such an approach in preclinical studies of ARDS specifically due to COVID-19 is especially important and timely.

CONCLUSIONS AND POTENTIAL RECOMMENDATIONS

SARS-CoV-2 binding to ACE2 may attenuate residual ACE2 activity, further tipping the ACE/ACE2 balance to a predominant ACE/AngII/AT1 axis signaling, in which AngII may then foster pulmonary vasoconstriction, and inflammatory and oxidative organ damage, ultimately progressing towards ALI/ARDS.⁵³ We speculate that RAAS dysregulation may play a central role in the pathophysiology of COVID-19 associated ALI/ARDS, but definitive studies that address this issue are needed. Whether RAAS modulation may have a beneficial effect in selected patients with severe COVID-19 at risk for ALI/ARDS is entirely unknown at the present time. Moreover, the effects of other agents that may interrupt the RAAS by inhibiting renin, such as renin inhibitors and beta-blockers, would also be of interest regarding their effects on COVID-19 and attendant ALI.

In agreement with current guidelines, patients with HTN should continue taking anti-HTN medications as prescribed without interruption. Current evidence shows that RAAS inhibitors, i.e., ACEIs and ARBs, significantly reduce mortality in CVD, reduce the progression of CKD, and are the cornerstone of HF and HTN treatment. ACEIs or ARBs therapy should be maintained or initiated, as indicated, in patients with HF, HTN, or myocardial infarction, regardless of SARS-CoV-2. No differences exist between ARBs and ACEIs in terms of efficacy to decrease BP and improve other outcomes, such as all-cause mortality, CVD mortality, myocardial infarction, HF, stroke, and end-stage renal disease.⁵⁸ ACEIs are associated with cough secondary to accumulation of bradykinin and angioedema, while withdrawal rates due to adverse events are lower with ARBs.⁵⁸ Given the equal efficacy but fewer adverse events, ARBs could potentially be a more favorable treatment option in COVID-19 patients at higher risk of developing severe forms of disease (Table 2). To further evaluate the role of RAAS modulation in COVID-19, datasets should be analyzed to investigate if use of ACEIs and ARBs on admission could be associated with ALI/ARDS and/or survival/mortality in patients with DM, HTN and CVD.

Finally, the potential utility of alternative therapies, such as recombinant ACE2, Ang 1-7 peptides, angiotensin II receptor inhibitors, and potentially aldosterone synthase inhibitors, for preventing or mitigating ALI caused by viruses, is entirely unknown at the present time and requires consideration and investigation for a disease for which current care is entirely supportive.

ACKNOWLEDGEMENTS

Fabian Sanchis-Gomar is supported by a postdoctoral contract granted by “*Subprograma Atracció de Talent - Contractes Postdoctorals de la Universitat de València.*”

Potential Competing Interests: The authors have no association with commercial entities that could be viewed as having an interest in the general area of the submitted manuscript.

REFERENCES

1. Shah A, Kashyap R, Tosh P, Sampathkumar P, O’Horo JC. Guide to Understanding the 2019 Novel Coronavirus. *Mayo Clin Proc.* 2020; doi: <https://doi.org/10.1016/j.mayocp.2020.02.003>.
2. Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. *BMJ.* 2020;368:m1036.
3. Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. *Ann Transl Med* 2020; doi: 10.21037/atm.2020.03.157.
4. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 62. Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>. Last accessed: March 25, 2020.
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA.* 2020;doi: 10.1001/jama.2020.2648.
6. Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. *New England Journal of Medicine.* 2020.
7. Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? *Eur Heart J.* 2020.

8. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J Virol.* 2020;94.
9. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front Med.* 2020.
10. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci.* 2020;12:8.
11. Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. *Biochem Biophys Res Commun.* 2020.
12. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med.* 2005;11:875-879.
13. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science.* 2020;367:1260-1263.
14. Velkoska E, Patel SK, Burrell LM. Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation. *Curr Opin Nephrol Hypertens.* 2016;25:384-395.
15. Tikellis C, Thomas MC. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. *Int J Pept.* 2012;2012:256294.
16. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circ Res.* 2000;87:E1-9.
17. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). *Hypertension.* 2003;42:574-579.
18. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. *Proc Natl Acad Sci U S A.* 2003;100:8258-8263.
19. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol.* 2004;203:631-637.
20. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. *Trends Pharmacol Sci.* 2004;25:291-294.
21. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell.* 2020.
22. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A.* 2020.
23. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol.* 2020.
24. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *The Lancet Respiratory Medicine.* 2020.
25. Watkins J. Preventing a covid-19 pandemic. *BMJ.* 2020;368:m810.

26. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? *J Hypertens*. 2020.
27. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020.
28. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020.
29. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.
30. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020.
31. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020.
32. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020.
33. Report sulle caratteristiche dei pazienti deceduti positivi a COVID-19 in Italia, 20 Marzo 2020. Available at: https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo.pdf. Last accessed: March 23, 2020.
34. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discovery*. 2020;6:14.
35. Hong M, Li W, Wang L, et al. Identification of a novel transcriptional repressor (HEPIS) that interacts with nsp-10 of SARS coronavirus. *Viral Immunol*. 2008;21:153-162.
36. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature*. 2002;417:822-828.
37. Diez-Freire C, Vazquez J, Correa de Adjoulian MF, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. *Physiol Genomics*. 2006;27:12-19.
38. Ferreira AJ, Shenoy V, Qi Y, et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. *Exp Physiol*. 2011;96:287-294.
39. Tikellis C, Pickering R, Tsorotes D, et al. Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. *Clin Sci (Lond)*. 2012;123:519-529.
40. Patel VB, Clarke N, Wang Z, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. *J Mol Cell Cardiol*. 2014;66:167-176.
41. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation*. 2005;111:2605-2610.
42. Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. *Hypertension*.

2006;48:572-578.

43. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. *Hypertension*. 2004;43:970-976.
44. Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. *Am J Physiol Renal Physiol*. 2009;296:F398-405.
45. Klimas J, Olvedy M, Ochodnicka-Mackovicova K, et al. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. *J Cell Mol Med*. 2015;19:1965-1974.
46. Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. *Clin Sci (Lond)*. 2012;123:649-658.
47. Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. *Eur Heart J*. 2005;26:369-375; discussion 322-364.
48. Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. *Europace*. 2017;19:1280-1287.
49. Ramchand J, Patel SK, Srivastava PM, Farouque O, Burrell LM. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. *PLoS One*. 2018;13:e0198144.
50. Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. *Hypertension*. 2014;64:1368-1375.
51. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. *Drug Dev Res*. 2020.
52. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci*. 2020;63:364-374.
53. Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. *Crit Care*. 2017;21:305.
54. Reddy R, Asante I, Liu S, et al. Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study. *PLoS One*. 2019;14:e0213096.
55. Stoll D, Yokota R, Sanches Aragao D, Casarini DE. Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG (1-7)/MAS receptor axes in human mesangial cells. *Physiol Rep*. 2019;7:e14105.
56. Xie X, Chen J, Wang X, Zhang F, Liu Y. Age- and gender-related difference of ACE2 expression in rat lung. *Life Sci*. 2006;78:2166-2171.

57. Gu H, Xie Z, Li T, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. *Sci Rep*. 2016;6:19840.

58. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? *J Am Coll Cardiol*. 2018;71:1474-1482.

59. Sparks MA, Hiremath S et al. The coronavirus conundrum: ACE2 and hypertension edition. *NephJC*. <http://www.nephjc.com/news/covidace2> . Accessed March 27, 2020.

Figure legends

Figure 1. Localization of ACE2 protein in human organs and tissues.

Figure 2. Scheme of Renin-Angiotensin-Aldosterone system and SARS-CoV-2 infection mechanism.

Table 1. Professional societies recommendations following the statements on the issue. ✓ Recommended continuing ARBs and ACEIs. ✓ Recommended continuing angiotensin receptor neprilysin inhibitors.

Adapted from *NephJC*.⁵⁹. Used with permission.

	Date of publication	Recommendation
European Society of Hypertension	March 12, 2020	✓
European Society of Cardiology Council on Hypertension	March 13, 2020	✓
Hypertension Canada	March 13, 2020	✓
Canadian Cardiovascular Society	March 15, 2020	✓ ✓
The Renal Association, United Kingdom	March 15, 2020	✓
International Society of Hypertension	March 16, 2020	✓
American College of Physicians	March 16, 2020	✓
Spanish Society of Hypertension	March 16, 2020	✓
American Heart Association	March 17, 2020	✓
Heart Failure Society of America	March 17, 2020	✓
American College of Cardiology	March 17, 2020	✓
European Renal Association, European Dialysis and Transplant Association	March 17, 2020	✓
High Blood Pressure Research Council of Australia	March 18, 2020	✓

Table 2. Risk factors related with worse prognosis in COVID-19 patients.

Age (>65 years)
Current smoker
Hypertension
Diabetes
Coronary heart disease
Atrial fibrillation
Chronic obstructive lung disease
Chronic kidney disease
Cancer
Obesity (BMI >30)




Figure 1







Figure 2


SARS-CoV-2





Fabian Sanchis
Fri 3/27/2020 4:10 PM

- Wentz, Margaret R. (Peg);
- Nath, Karl A., M.D.

+4 others 
Hi Peg,

Here is the permission to use table 1 (see below). The authors would prefer we cite it as:

Sparks MA, Hiremath S et al. "The Coronavirus Conundrum: ACE2 and Hypertension Edition" NephJC <http://www.nephjc.com/news/covidace2> *with access date*

Access date: whenever you access it as the document is being updated daily or so

Let me know if this is ok and do not hesitate to contact me if you need anything else.

Best regards,

Fabian

Fabian Sanchis-Gomar, MD, MSc, PhD
Department of Medicine
Stanford University Medical Center
300 Pasteur Drive, S-102
Stanford, California 94305-5110
Office Phone: (650) 725-4515
Cell Phone: (408) 439-5760

Department of Physiology, School of Medicine, University of Valencia
INCLIVA Biomedical Research Institute
Avda. Blasco Ibañez, 15, 46010, Valencia, Spain
Phone: 695813115
E-mail: fabian.sanchis@uv.es

Connect via [Research Gate](#) | [Google Scholar](#) | [Twitter](#) | [Linkedin](#)

This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, or distribution is prohibited. If you are not the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message, including any attachments.

De: Nephrology JC <nephrologyjc@gmail.com>
Fecha: viernes, 27 de marzo de 2020, 13:57
Para: Fabian Sanchis <fabian.sanchis@uv.es>
Asunto: Re: Permission to used an adapted version of a table of your website

Hi Fabian
Please go ahead
We would prefer you cite it as

Sparks MA, Hiremath S et al. "The Coronavirus Conundrum: ACE2 and Hypertension Edition"
NephJC <http://www.nephjc.com/news/covidace2> *with access date*

Access date: whenever you access it as the document is being updated daily or so

Swapnil

On Mar 27, 2020, at 11:31 AM, Fabian Sanchis <fabian.sanchis@uv.es> wrote:

Dear Sir or Madam,

I'm planning to publish a manuscript on ACE inhibitors use in COVID-19 and I would like to ask if I could use your table (PDF #1 attached) on professional societies statements on the topic. I've simplified and adapted it (see also my table, PDF #2 attached). Obviously, your website will be also cited.

Please let me know at your earlier convenience.

With my best wishes,

Fabian Sanchis-Gomar, MD, MSc, PhD
Department of Medicine
Stanford University Medical Center
300 Pasteur Drive, S-102
Stanford, California 94305-5110
Office Phone: (650) 725-4515

Cell Phone: (408) 439-5760

Department of Physiology, School of Medicine, University of Valencia
INCLIVA Biomedical Research Institute
Avda. Blasco Ibañez, 15, 46010, Valencia, Spain
Phone: 695813115
E-mail: fabian.sanchis@uv.es

Connect via [Research Gate](#) | [Google Scholar](#) | [Twitter](#) | [Linkedin](#)

This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, or distribution is prohibited. If you are not the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message, including any attachments.

<#1 Table.pdf>

<#2 Table.pdf>